Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets slump further
Fri, 12 Apr 01:30 pm

Weak market sentiments from poor Infosys results were further compounded by a marginal 0.6% rise in the Index of Industrial Production for February 2013. Thus, Indian share markets remained in a free-fall in the post-noon trading session. Majority of the sectoral indices are trading negative with IT, realtyand capital goods stocks being the major losers. FMCG, oil and gas and banking are among the few stocks trading in the green.

BSE-Sensex is down 335 points and NSE-Nifty is trading down 79 points. While BSE Mid Cap is down 0.5%, BSE Small Capindex is trading down by 0.6%. The rupee is trading at 54.4 to the US dollar.

Steel stocks are trading mixed with Adhunik Metaliks and JSW Steel being the biggest gainers and Tayo Rolls and Maharashtra Seamless leading in losses. The World Steel Association (WSA) has projected steel demand in India to gain momentum in 2013 and grow by 5.9% to 75.8 m tonnes. The pick-up will be aided by increased investments from easing monetary policies. In 2012, steel demand had increased by 2.5%. WSA expects growth in domestic steel demand to further accelerate to 7% in 2014 on the back of reform measures to improve fiscal deficit and foreign direct investments. The global steel body has projected the world steel demand to grow at a relatively muted pace of 2.9% and 3.2% in 2013 and 2014, respectively.

Indian pharma stocks Indian Pharma - Live Stock Quotes and Analysis Update from Equitymaster.com are trading mixed with Elder Pharma and Aurobindo Pharma being the leading gainers while Wockhardt Ltd and Strides Acrolab are top losers. As per a financial daily, Dr Reddy's Labs (DRL) has initiated recall of tizanidine tablets from the US market. This drug is used as muscle relaxant. Reportedly, the recall has been voluntarily, initiated by the company. Approx 117,000 bottles (150 tablets per bottle) are being recalled. The said recall was done as some labelling information was missing and thus was categorized under a Class-III recall as per USFDA (United States Food and Drugs Administration) norms. As per the USFDA, a Class-III recall is done in a situation in which "use of or exposure to a violative product is not likely to cause adverse health consequences". The stock of Dr Reddy's was trading up by 0.3%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets slump further". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.